<DOC>
	<DOCNO>NCT00102310</DOCNO>
	<brief_summary>The primary objective study characterize dose response profile YM443 subject functional dyspepsia ( FD ) enable selection dose Phase 3 clinical trial .</brief_summary>
	<brief_title>YM443 Subjects With Functional Dyspepsia</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Dyspepsia</mesh_term>
	<criteria>Ability read write English . Written inform consent obtain . 1875 year age day Informed Consent Form sign . Men woman . Females , pregnant , lactate likely become pregnant . Abdominal ultrasound and/or upper endoscopy finding judge clinically significant Investigator Screening within 4 week prior Screening . Symptoms FD Visits 1 4 define Rome II criterion . Subjects positive H. pylorus breath test Screening may include study . Subjects pHmetry result Screening indicative reflux may include study . ECG , vital sign , laboratory result judge clinically significant Investigator Screening . Significant renal , hepatic , bilirubin , cardiovascular , pulmonary , endocrine , metabolic , hematological , neurologic , gastrointestinal ( one study ) condition . Subjects diabetes mellitus exclude . Congenital acquire long QT syndrome , uncontrolled arrhythmia . Prior surgery luminal GI tract . History major psychiatric disorder , current depression anxiety , alcohol abuse , substance abuse last 2 year . Any evidence treatment malignancy ( exception basal cell carcinoma ) within last 5 year . Confirmed structural gastrointestinal disease . Predominant symptoms irritable bowel syndrome ( IBS ) ( Rome II criterion ) gastroesophageal reflux disease ( GERD ) assess Visit 1 4 . Female subject pregnant , lactating , likely become pregnant study . Males females childbearing potential must abstinent agree use contraceptive regimen throughout study . Any history condition , opinion Investigator , make subject unsuitable procedure use study would allow safe completion study . Known hypersensitivity gastroprokinetics proton pump inhibitor . Use antiulcer medication , antacid/acid suppression medication , gastroprokinetics , aspirin ( &gt; 325 mg daily ) , NSAIDs , antibiotic , medication effect GI system within 2 week prior Screening . Must able stay medication study , except proton pump inhibitor ( PPIs ) administer PPI Runin Period . Required use concomitant medication know adversely interact gastroprokinetic agent proton pump inhibitor . H. pylori eradication therapy ( PPIs , antibiotic , bismuth preparation ) 2 week prior upper endoscopy . Treatment H. pylorus require study . Subject receive investigational drug within 30 day 10 halflives , ever long , participate 3 clinical study within 12 month , prior Visit 1 . Previous treatment YM443 . Employees Yamanouchi Group CROs involve study . More one subject per household participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Nausea</keyword>
	<keyword>Indigestion</keyword>
	<keyword>Bloating</keyword>
	<keyword>Functional Dyspepsia</keyword>
	<keyword>Fullness Meals</keyword>
</DOC>